Related Experiment Video
Updated: May 26, 2026
05:44
Formation of Dispersible Taohong Siwu Tablets
Published on: February 3, 2023
Development and evaluation of sustained-release Compritol® 888 ATO matrix mini-tablets
Matthew Roberts1, Daniele Vellucci, Shabbir Mostafa
1School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK. m.roberts1@ljmu.ac.uk
Drug Development and Industrial Pharmacy
|December 14, 2011
Summary
Sustained-release matrix mini-tablets offer tailored drug delivery for pediatric use. Adjusting Compritol® 888 ATO concentration and mini-tablet size controls drug release rates for effective formulations.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
Background:
- Sustained-release mini-tablets are promising for pediatric drug delivery and multi-particulate dosage forms.
- Lipophilic matrix systems offer potential for controlled drug release.
Purpose of the Study:
- To explore the development of lipophilic matrix mini-tablets.
- To investigate the impact of Compritol® 888 ATO concentration on drug release.
- To assess the effect of mini-tablet size on drug release kinetics.
Main Methods:
- Theophylline was used as a model soluble drug.
- Compritol® 888 ATO (15-45% w/w) was employed as a matrix-forming agent.
- Mini-tablets of varying sizes (2-4 mm) were prepared by direct compression.
Main Results:
- Drug release was sustained for 12 hours from matrix tablets.
- Higher Compritol® 888 ATO concentrations resulted in slower drug release rates.
- Drug release rate was inversely proportional to mini-tablet size (2 mm > 3 mm > 4 mm).
- Drug release followed square-root of time kinetics for both tablets and mini-tablets.
Conclusions:
- Drug release can be precisely controlled by modifying mini-tablet size and Compritol® 888 ATO content.
- These findings support the potential of matrix mini-tablets in pediatric formulations and multi-particulate dosage forms.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...